. (2015). Erratum: Borderud SP, Li Y, Burkhalter JE, Sheffer CE and Ostroff JS. Electronic cigarette use among patients with cancer: Characteristics of electronic cigarette users and their smoking cessation outcomes. Cancer. doi: 10.1002/ cncr.28811. Cancer. 121 [PubMed]
Bezzi P et al. (2001). CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nature neuroscience. 4 [PubMed]
Clark IA. (2007). How TNF was recognized as a key mechanism of disease. Cytokine & growth factor reviews. 18 [PubMed]
Dufty BM et al. (2007). Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. The American journal of pathology. 170 [PubMed]
Fischer R, Maier O. (2015). Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxidative medicine and cellular longevity. 2015 [PubMed]
GBD 2016 Parkinson's Disease Collaborators. (2018). Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Neurology. 17 [PubMed]
Hanisch UK. (2002). Microglia as a source and target of cytokines. Glia. 40 [PubMed]
Harms AS et al. (2011). Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Molecular therapy : the journal of the American Society of Gene Therapy. 19 [PubMed]
He J, Zhong W, Zhang M, Zhang R, Hu W. (2018). P38 Mitogen-activated Protein Kinase and Parkinson's Disease. Translational neuroscience. 9 [PubMed]
Hirsch EC. (2000). Glial cells and Parkinson's disease. Journal of neurology. 247 Suppl 2 [PubMed]
Inoue K. (2002). Microglial activation by purines and pyrimidines. Glia. 40 [PubMed]
Izumi Y et al. (2009). Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and MAPK activation. Journal of neurochemistry. 110 [PubMed]
Ji Z, Yan K, Li W, Hu H, Zhu X. (2017). Mathematical and Computational Modeling in Complex Biological Systems. BioMed research international. 2017 [PubMed]
Junn E, Mouradian MM. (2001). Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. Journal of neurochemistry. 78 [PubMed]
Kouchaki E et al. (2018). Increased serum levels of TNF-a and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. Clinical neurology and neurosurgery. 166 [PubMed]
Leal MC, Casabona JC, Puntel M, Pitossi FJ. (2013). Interleukin-1ß and tumor necrosis factor-a: reliable targets for protective therapies in Parkinson's Disease? Frontiers in cellular neuroscience. 7 [PubMed]
Lindenau JD, Altmann V, Schumacher-Schuh AF, Rieder CR, Hutz MH. (2017). Tumor necrosis factor alpha polymorphisms are associated with Parkinson's disease age at onset. Neuroscience letters. 658 [PubMed]
Nagatsu T, Sawada M. (2007). Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. Journal of neural transmission. Supplementum. [PubMed]
Negro S et al. (2016). ATP Released by Injured Neurons Activates Schwann Cells. Frontiers in cellular neuroscience. 10 [PubMed]
Olmos G, Lladó J. (2014). Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediators of inflammation. 2014 [PubMed]
Parent A, Parent M, Charara A. (1999). Glutamatergic inputs to midbrain dopaminergic neurons in primates. Parkinsonism & related disorders. 5 [PubMed]
Perez RG et al. (2002). A role for alpha-synuclein in the regulation of dopamine biosynthesis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22 [PubMed]
Peter I et al. (2018). Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. JAMA neurology. 75 [PubMed]
Qian L, Flood PM. (2008). Microglial cells and Parkinson's disease. Immunologic research. 41 [PubMed]
Ragothaman M, Govindappa ST, Rattihalli R, Subbakrishna DK, Muthane UB. (2006). Direct costs of managing Parkinson's disease in India: concerns in a developing country. Movement disorders : official journal of the Movement Disorder Society. 21 [PubMed]
Sasidharakurup H, Melethadathil N, Nair B, Diwakar S. (2017). A Systems Model of Parkinson's Disease Using Biochemical Systems Theory. Omics : a journal of integrative biology. 21 [PubMed]
Smith PD et al. (2003). Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 100 [PubMed]
Stayte S, Vissel B. (2014). Advances in non-dopaminergic treatments for Parkinson's disease. Frontiers in neuroscience. 8 [PubMed]
Takeuchi H et al. (2006). Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. The Journal of biological chemistry. 281 [PubMed]
Vincent VA, Tilders FJ, Van Dam AM. (1997). Inhibition of endotoxin-induced nitric oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor beta. Glia. 19 [PubMed]
Welser-Alves JV, Milner R. (2013). Microglia are the major source of TNF-a and TGF-ß1 in postnatal glial cultures; regulation by cytokines, lipopolysaccharide, and vitronectin. Neurochemistry international. 63 [PubMed]
Wood LB, Winslow AR, Strasser SD. (2015). Systems biology of neurodegenerative diseases. Integrative biology : quantitative biosciences from nano to macro. 7 [PubMed]